Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of ...
ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...
Please provide your email address to receive an email when new articles are posted on . Patients with IBD who received rapid infusions of infliximab were not at elevated risk for infusion reaction ...
HORSHAM, PA and KENILWORTH, NJ, NOVEMBER 6, 2007—Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now ...
Infliximab is medicine used for many inflammatory or immune problems, such as certain types of arthritis, gut conditions, and skin conditions. Common side effects include infections, headache, or ...
Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...
In a double-blind multicenter study by Targan et al., [50] 108 patients with active, refractory, moderate to severe CD (a mean CDAI score at baseline of approximately 300 despite treatment with ...
MALVERN, Pa.--(BUSINESS WIRE)--Dec. 20, 2004--Centocor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved REMICADE(R) (infliximab) for the treatment of ankylosing ...
July 11, 2002 -- The U.S. Food and Drug Administration (FDA) has granted marketing approval to infliximab (Remicade) to provide long-term remission-level control of moderate to severe Crohn's disease.
-- Revised Labeling Allows Crohn's Patients to Benefit from REMICADE When They Do Not Respond to a Full and Adequate Course of Therapy with a Corticosteroid and/or an Immunosuppressant Centocor, Inc.
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window PHILADELPHIA, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback